THE POTENTIAL APPLICATIONS OF US MRNA VACCINES IN CHINA AND IMPLICATIONS FOR A “UNIVERSAL” COVID VACCINE
Received: 25th August 2023; Revised: 02nd November 2023, 28th November 2023; Accepted: 12th December 2023
DOI:
https://doi.org/10.20319/lijhls.2024.8.111124Keywords:
MRNA Vaccines, COVID-19, SARS-COV-2, NCBIAbstract
The resurgence of Covid outbreak in China at the start of 2023 with the new XBB variants made people question the effectiveness of the Sinopharm vaccine. In this paper, I tried to investigate the applicability of the US mRNA vaccinations in the Chinese population, and the implication of the development of a universal Covid vaccine. I blasted the selected BA.2.12.1 strain’s genome and spike protein sequences of China’s, Japan’s and the US’s (NY, CA, WA and AZ) strains from the NCBI SARS-CoV-2 database. Blast results showed a high percentage (>0.95) of alignment among the complete genome and spike protein sequences from all the selected regions, which supported the ideas of the applications of one mRNA vaccine to target the dominant strain in different countries. On the other hand, the identification of certain point mutations (R343T, G679R) in the functional and structural part of the spike protein underlined the high mutability of the virus as it spreads across continents. These findings suggested that while mRNA vaccines could be more effective for the prevailing strain in China and potentially the rest of the world, in order to make a firm conclusion and medical plan for the implementation, it still required additional trials and research with more data.
References
Commissioner, O. of the. (2023). COVID-19 Bivalent Vaccines. FDA. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 among Hospitalized Adults Aged ≥65 Years—United States, January–March 2021 | MMWR. (n.d.). Retrieved June 29, 2023, from https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm?back=https%3A%2F%2Fwww.google.com%2Fsearch%3Fclient%3Dsafari%26as_qdr%3Dall%26as_occt%3Dany%26safe%3Dactive%26as_q%3Dvaccines+protect+against+hospitalization%26channel%3Daplab%26source%3Da-app1%26hl%3Den#F1_down
Francis, A. I., Ghany, S., Gilkes, T., & Umakanthan, S. (2022). Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgraduate Medical Journal, 98(1159), 389–394. https://doi.org/10.1136/postgradmedj-2021-140654
Huang, Y., Yang, C., Xu, X., Xu, W., & Liu, S. (2020). Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41(9), Article 9. https://doi.org/10.1038/s41401-020-0485-4
Hyams, C., Challen, R., Marlow, R., Nguyen, J., Begier, E., Southern, J., King, J., Morley, A., Kinney, J., Clout, M., Oliver, J., Gray, S., Ellsbury, G., Maskell, N., Jodar, L., Gessner, B., McLaughlin, J., Danon, L., Finn, A., … Szasz-Benczur, Z. (2023). Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. The Lancet Regional Health – Europe, 25. https://doi.org/10.1016/j.lanepe.2022.100556
Omicron, Delta, Alpha, and More: What To Know About the Coronavirus Variants. (n.d.). (2023) Yale Medicine. Retrieved June 27, 2023, from https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron
Omicron WHAT? A users’ guide to COVID-19 variant names | Gavi, the Vaccine Alliance. (n.d.). (2023) Retrieved July 24, 2023, from https://www.gavi.org/vaccineswork/omicron-what-users-guide-covid-19-variant-names
Tenforde, M. W. (2021). Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 among Hospitalized Adults Aged ≥65 Years—United States, January–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70. https://doi.org/10.15585/mmwr.mm7018e1
The Janssen Ad26. (2023). COV2.S COVID-19 vaccine: What you need to know. (n.d.). Retrieved June 29, 2023, from https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know
Twohig, K. A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M. A., Aliabadi, S., Seaman, S. R., Harris, R. J., Hope, R., Lopez-Bernal, J., Gallagher, E., Charlett, A., Angelis, D. D., Presanis, A. M., Dabrera, G., Koshy, C., Ash, A., Wise, E., Moore, N., … Gunson, R. (2022). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. The Lancet Infectious Diseases, 22(1), 35–42. https://doi.org/10.1016/S1473-3099(21)00475-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Nan Xiang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of Published Articles
Author(s) retain the article copyright and publishing rights without any restrictions.
All published work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
